This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

NovaBay Pharmaceuticals Provides Fourth Quarter And Full Year 2010 Financial Results And Business Unit Updates

NovaBay is focusing its technology on four distinct therapeutic areas:  dermatology, ophthalmology, urology and hospital infections.  In dermatology, the focus is on developing NVC-422 gel for impetigo and acne.  NovaBay has the distinct advantage of being partnered with Galderma, the leading dermatology company in the world.  In ophthalmology, the goal is to develop an eye drop for conjunctivitis with Alcon, the world's leading ophthalmology company.  In urology, NovaBay aims to reduce the incidence of urinary catheter blockage and encrustation (UCBE) and the associated urinary tract infections with an irrigation solution containing NVC-422.  In hospital infection, NovaBay is targeting the six-million-patient market of chronic non-healing wounds, such as pressure, venous stasis and diabetic ulcers with its proprietary antimicrobial solution, NeutroPhase ®, which has received two 510K clearances from the Food and Drug Administration. Visit .

Forward-Looking Statements

This release contains forward-looking statements, which are based upon management's current expectations, assumptions, estimates, projections and beliefs. Statements regarding NovaBay's expectations including, but not limited to, (i) any potential plans for future clinical development of its Aganocide compounds and of bringing products to market including the expected timing or the results of the Phase 2b impetigo clinical trial and Phase 2 conjunctivitis trial; (ii) that Alcon and NovaBay will announce the results of the viral conjunctivitis clinical trial during the first half of 2011; (iii) the potential that the full data will differ from the interim data,(iv) the potential efficacy of Aganocide & Neutrophase compounds, (v) NovaBay's plan to commercialize Neutrophase in 2011 resulting in its availability to the 6 million patients suffering from diabetic, pressure, and venous stasis ulcers in early 2012 and potential revenue from its sales in 2012.; (vi) that the strategy of multiple product opportunities has the potential to increase NovaBay's probability of success and decrease risk of shareholder investment;  (vii) its cash burn (viii) the development and potential benefits of, and the market opportunities for, NovaBay's product candidates (ix) the potential to deliver the same or better efficacy than antibiotics and to address the growing problem of antibiotic resistance as well as other statements that relate to future events or results, are forward-looking. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to: the risk that NovaBay may incur unexpected charges or need to or determined to engage in research and development not previously planned, which will cause NovaBay's cash burn to be greater than it expects; the risk that negative results from the development programs could preclude Galderma and Alcon from providing additional funding to NovaBay; inherent risks and uncertainties relating to difficulties or delays in conducting clinical trials; the inherent uncertainty of patent protection for the company's intellectual property or trade secrets, risks and uncertainties relating to difficulties or delays in discovery, development, testing, production and marketing of the company's product candidates; unexpected adverse side effects or inadequate therapeutic efficacy of the product candidates; the company's ability to obtain additional financing as necessary; results obtained in animal models may not be obtained in humans; and the risk of unexpected delays in the regulatory process which may delay the commencement or completion of clinical trials. Other risks relating to NovaBay and Aganocide® compounds, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay's Annual Report on Form 10-K for the period ended December 31, 2010, under the caption "Risk Factors" in Item 1A of Part I of that report, filed with the Securities and Exchange Commission on March 10, 2011. The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.
(a development stage company)
(in thousands, except per share data)
  December 31,
  2010 2009
Current assets:    
Cash and cash equivalents  $ 11,534  $ 10,992
Short-term investments  1,272  300
Accounts receivable  500  3,750
Prepaid expenses and other current assets  448  564
Total current assets  13,754  15,606
Property and equipment, net  1,588  1,812
Other assets  174  105
TOTAL ASSETS  $ 15,516  $ 17,523
Current liabilities:    
Accounts payable  $ 406  $ 272
Accrued liabilities  726  1,228
Capital lease obligation  --   7
Equipment loan  106  364
Deferred revenue  1,485  2,167
Total current liabilities  2,723  4,038
Deferred revenue - non-current  2,204  -- 
Deferred rent  99  -- 
Equipment loan - non-current  --  106
Deferred tax liability   --   34
Total liabilities  5,026  4,178
Stockholders' Equity:    
Preferred stock, $.01 par value; 5,000 shares authorized; none outstanding at December 31, 2010 or 2009  --   --
Common stock, $0.01 par value; 65,000 shares authorized at December 31, 2010 and 2009; 23,392 and 23,254 shares issued and outstanding at December 31, 2010 and 2009, respectively  234  233
Additional paid-in capital  38,469  37,003
Accumulated other comprehensive loss  (14)  -- 
Accumulated deficit during development stage  (28,199)  (23,891)
Total stockholders' equity  10,490  13,345
(a development stage company)
(in thousands, except per share data)
        Cumulative Period
         from July 1, 2002
         (inception) to
  Year Ended December 31,  December 31,
  2010 2009 2008 2010
License and collaboration revenue:  $ 9,754  $ 15,684  $ 6,722  $ 39,606
Operating Expenses:        
Research and development  8,616  7,337  9,595  40,960
General and administrative  5,654  5,607  5,636  28,225
Total operating expenses  14,270  12,944  15,231  69,185
Operating income (loss)  (4,516)  2,740  (8,509)  (29,579)
Other income (expense), net  258  (36)  397  1,451
Income (loss) before income taxes  (4,258)  2,704  (8,112)  (28,128)
Income tax provision  (50)  (7)  (2)  (71)
Net income (loss)   $ (4,308)  $ 2,697  $ (8,114)  $ (28,199)
Net income (loss) per share:        
Basic  $ (0.18)  $ 0.12  $ (0.38)  
Diluted  $ (0.18)  $ 0.12  $ (0.38)  
Shares used in computing net income (loss) per share:      
Basic  23,326  22,404  21,312  
Diluted  23,326  23,115  21,312  
CONTACT: Investors:
         NovaBay Pharmaceuticals, Inc.
         Tom Paulson
         Chief Financial Officer
         Investors and Media:
         The Investor Relations Group
         11 Stone St. 3rd Floor
         New York, NY
         IR: Adam Holdsworth
         PR: Laura Colontrelle/Janet Vasquez

4 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,084.49 +33.74 0.20%
S&P 500 2,013.43 +15.91 0.80%
NASDAQ 4,830.47 +19.6820 0.41%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs